Abstract
Background. The unquestionable benefit of antiretroviral therapy in reducing the rate of mother-to-child transmission can be lessened by potential maternal or neonatal toxicity. Objective. To analyze obstetric and perinatal complications in a cohort of HIV-infected pregnant women and their relationship with maternal antiretroviral therapy. Population. One hundred and sixty-seven HIV-infected pregnant women who delivered at Hospital Universitario La Paz, Madrid, Spain between January 1997 and December 2003. Methods. Data on the clinical and epidemiological characteristics of HIV-infected patients, previous and current antiretroviral therapy, gestational diabetes mellitus, length of pregnancy, mode of delivery, and weight of the newborn were collected. Pregnancy outcomes were compared with those of all the pregnant women attended at our hospital. Main outcome measures. Gestational diabetes mellitus, premature delivery, and low birth weight. Results. Gestational diabetes mellitus was diagnosed in 8.9% of patients. All the cases of gestational diabetes were in the combined antiretroviral therapy group, and the majority were receiving triple antiretroviral therapy with a protease inhibitor. The risk of developing this pathology was greater among women receiving antiretroviral therapy prior to pregnancy. The premature delivery rate was 29% and the low birth weight rate was 28%. Conclusion. Gestational diabetes mellitus is more common in HIV-infected women than in the general population and is related to combined antiretroviral therapy, especially the use of protease inhibitors, which suggests the need for close follow-up during pregnancy in HIV-infected patients. Nevertheless, the adverse perinatal consequences observed were more related to maternal factors than to antiretroviral therapy.
| Abbreviations | ||
| ART | = | antiretroviral therapy |
| AZT | = | zidovudine |
| BMI | = | body mass index |
| GDM | = | gestational diabetes mellitus |
| GCT | = | 50-g glucose challenge test |
| HIV | = | human immunodeficiency virus |
| HCV | = | hepatitis C virus |
| MTCT | = | mother-to-child transmission |
| NRTIs | = | nucleoside reverse transcriptase inhibitors |
| NNRTI | = | non-nucleoside reverse transcriptase inhibitor |
| OGTT | = | 3-h 100-g oral glucose tolerance test |
| PI | = | protease inhibitor |
| PACTG | = | Pediatric AIDS Clinical Trial Group |
| WITS | = | Women and Infant Transmission Study |
| Abbreviations | ||
| ART | = | antiretroviral therapy |
| AZT | = | zidovudine |
| BMI | = | body mass index |
| GDM | = | gestational diabetes mellitus |
| GCT | = | 50-g glucose challenge test |
| HIV | = | human immunodeficiency virus |
| HCV | = | hepatitis C virus |
| MTCT | = | mother-to-child transmission |
| NRTIs | = | nucleoside reverse transcriptase inhibitors |
| NNRTI | = | non-nucleoside reverse transcriptase inhibitor |
| OGTT | = | 3-h 100-g oral glucose tolerance test |
| PI | = | protease inhibitor |
| PACTG | = | Pediatric AIDS Clinical Trial Group |
| WITS | = | Women and Infant Transmission Study |